Sancuso Transdermal System: Protection for Your Patients
Learn how Sancuso Transdermal System provides compliance, convenience, and efficacy for patients undergoing chemotherapy to prevent CINV2,3
Proven Chemo-Induced Nausea and Vomiting (CINV) Prevention1
Sancuso has more than a decade and a half of proven experience in preventing CINV
Proven Efficacy2
83.9% of patients obtained complete control* of CINV at Day 5 of Sancuso treatment
Consistent and Predictable Through 5 Days3
Sancuso avoids the peak-trough fluctuations in blood levels seen with daily oral granisetron
Sancuso Access Options
Streamlined access to ensure patients get what they need
Sancuso Patient Rx Solutions™
Sancuso Patient Rx Solutions™ streamlines patient access to Sancuso by offering comprehensive support. Our concierge services help reduce administrative burden, ensuring your patients receive the treatment they need without delays. Enroll your patients today to simplify the prescription process and improve adherence.
Request a Sancuso Account Manager
To request a Sancuso representative, please click below and request via email, including name and office information.
Sancuso Rapid Access Sample Portal
Request a Sancuso sample through our Sancuso Sample Portal. For assistance navigating the portal, click HERE.
Sancuso Patient Access CoPay Coupon
Eligible patients may save up to $300 per patch on Sancuso after paying the first $20 per prescription. Maximum savings of $1200 per month for 4 or more patches.
INDICATIONS AND USAGE
SANCUSO (granisetron transdermal system) is indicated for the prevention of nausea and vomiting in adults receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
SANCUSO is contraindicated in patients with known hypersensitivity to granisetron or to any of the components of the transdermal system.
WARNINGS AND PRECAUTIONS
PROGRESSIVE ILEUS AND GASTRIC DISTENTION: Sancuso may mask a progressive ileus and/or gastric distention. This should be particularly considered before use of Sancuso in patients who have had recent abdominal surgery. Monitor for decreased bowel activity, particularly in patients with risk factors for gastrointestinal obstruction.
SEROTONIN SYNDROME: The development of serotonin syndrome has been reported with 5-HT3 receptor antagonists. Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of sancuso and other serotonergic drugs. If symptoms of serotonin syndrome occur, discontinue Sancuso and initiate supportive treatment. Patients should be informed of the increased risk of serotonin syndrome, especially if Sancuso is used concomitantly with other serotonergic drugs.
SKIN REACTIONS: In clinical trials with Sancuso, application site reactions were reported that were generally mild in intensity and did not lead to discontinuation of use. The incidence of reactions was comparable with placebo. If severe reactions, or a generalized skin reaction occur (e.g., allergic rash, including erythematous, macular, papular rash or pruritus), remove the Sancuso transdermal system.
INCREASED DRUG EXPOSURE WITH USE OF EXTERNAL HEAT SOURCES: Prolonged exposure to heat results in increasing plasma concentrations of granisetron during the period of heat exposure. Do not apply a heat pad or heat lamp over or in the vicinity of the Sancuso transdermal system and avoid extended exposure to heat.
PHOTOTOXICITY WITH ULTRAVIOLET LIGHT EXPOSURE: Granisetron may be affected by direct natural or artificial sunlight, including sunlamps. An in vitro study using Chinese hamster ovary cells suggests that granisetron has the potential for photogenotoxicity. To avoid a potential skin reaction, advise patients to cover the application site of the transdermal system with clothing if there is a risk of exposure to direct natural or artificial sunlight throughout the period of wear and for 10 days following its removal.
ADVERSE REACTIONS
The most common adverse reaction (≥ 5%) is constipation.
You are encouraged to report suspected adverse reactions to Cumberland Pharmaceuticals, Inc. at 1-833-Sancuso or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
*In the phase 3 trial, the primary endpoint was complete control, which is defined as no vomiting/retching, no more than mild nausea, and no rescue medication needed from first dose to 24 hours after last dose of chemotherapy1
REFERENCES
- Sancuso [package insert]. Nashville, TN, Cumberland Pharmaceuticals Inc.; 2024.
- Boccia RV, Gordon LN, Clark G, Howell JD, Grun SM; on behalf of the Sancuso Study Group. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy; a randomized, double-blind, phase III study. Support Care Cancer. 2011;19(10):1609-1617.
- Mason JW, Moon TE. Use and cardiovascular safety of transdermal and other granisetron preparations in cancer management. Cancer Manag Res. 2013;5:179-185.
Have Questions or Would like to Stay Informed About Sancuso?
We’re Here to Help!
Have Questions or Would like to Stay Informed About Sancuso?
We’re Here to Help!
